Immunovia's Next-Generation Pancreatic Cancer Test Shows Promising Results in VERIFI Study
Immunovia, a pioneering company in pancreatic cancer diagnostics, has recently unveiled further promising data from the VERIFI study, significantly bolstering its reputation ahead of the anticipated commercial launch of its next-generation pancreatic cancer test. This innovative blood test has demonstrated remarkable capabilities, detecting a higher rate of cancers compared to CA19-9, which is the established biomarker for pancreatic cancer.
The VERIFI study has shown that Immunovia's test meets its primary study endpoint, successfully identifying 77% of stage I and II pancreatic cancer cases. This result far exceeds the initial target of 65%, marking an impressive advancement in early detection methods for this notoriously aggressive type of cancer. In comparison, CA19-9 had a sensitivity of only 69%, highlighting the superior efficacy of Immunovia's test.
Jeff Borcherding, CEO of Immunovia, expressed confidence in the new test's potential, stating that it has accurately classified both cancerous and non-cancerous samples during the study. This advancement not only strengthens Immunovia’s position in the market but also emphasizes the test's applicability across diverse high-risk populations, such as those with a family history of pancreatic cancer, genetic predispositions, diabetes, or existing pancreatic cysts.
In a remarkable first, combined results from both the VERIFI and the preceding CLARITI validation studies provide a comprehensive view of the test’s performance across various groups of high-risk patients. According to the data, the test demonstrated consistent sensitivity and specificity that can aid in the accurate detection of pancreatic cancer for individuals categorized into different high-risk groups. The overall results reveal that from a total of 317 cases and 1,134 controls, the test achieved a sensitivity of 78% along with an impressive specificity of 92%.
Breaking down the results further highlights the test’s efficiency in specific demographics. For individuals with a familial or genetic risk factor, sensitivity remained at 78% with a specificity of 94%. In patients suffering from diabetes, the sensitivity reached 80%, with a specificity of 90%. Lastly, individuals with pancreatic cysts saw sensitivity at 72% and specificity at 89%.
What stands out is that the specificity observed in the VERIFI study aligns closely with the performance benchmark set by CA19-9, only slightly below the target of 90% with Immunovia’s test recording a specificity of 88%. Borcherding reiterated the significance of this achievement, asserting that such promising accuracy data enhances Immunovia’s commercial prospects and broadens the market it can serve.
Looking to the future, Immunovia is gearing up for the commercial launch of its pancreatic cancer blood test, expected in the third quarter of 2025. The company is committed to conducting further clinical studies to validate the clinical impact of this groundbreaking test and establish its efficacy in other high-risk populations. These forthcoming studies will not only support important regulatory filings but also drive the company's efforts in securing payer reimbursement to facilitate broader access to this vital testing. Alongside these developments, Immunovia is seeking potential commercial partnerships to expedite the uptake of its revolutionary test in the healthcare market.
The VERIFI study itself, which involved the analysis of 385 blood samples collected from six prominent pancreatic cancer research centers across the United States, underlines the rigor behind the research methodology. Among those samples, a total of 115 originated from patients diagnosed with stage I and II pancreatic ductal adenocarcinoma, commonly regarded as the predominant form of pancreatic cancer. These were effectively contrasted with 270 control samples from high-risk individuals who did not have the disease, including those with relevant family histories, gene mutations, or existing pancreatic cysts.
Pancreatic cancer continues to pose a significant threat, marked by a grim five-year survival rate of only 13%. As such, early detection remains a cornerstone for improving patient outcomes. Immunovia's dedication to developing this next-generation test is a crucial step in equipping healthcare professionals with the necessary tools to identify this disease in its nascent stages, particularly for individuals with heightened risks due to genetic factors or previously existing pancreatic conditions. The company estimates over 1.8 million individuals in the United States are at a high-risk threshold for pancreatic cancer, indicating a robust market demand for their innovation.
In conclusion, Immunovia is at the forefront of a paradigm shift in pancreatic cancer diagnostics, committed to enhancing survival through early detection. The testimonies from the success of the VERIFI study mark a significant milestone for the company and offer hope for countless patients at risk. For more details or inquiries, interested parties can contact Jeff Borcherding, CEO and President of Immunovia, through the provided contact channels, or visit their official website.
The VERIFI study has shown that Immunovia's test meets its primary study endpoint, successfully identifying 77% of stage I and II pancreatic cancer cases. This result far exceeds the initial target of 65%, marking an impressive advancement in early detection methods for this notoriously aggressive type of cancer. In comparison, CA19-9 had a sensitivity of only 69%, highlighting the superior efficacy of Immunovia's test.
Jeff Borcherding, CEO of Immunovia, expressed confidence in the new test's potential, stating that it has accurately classified both cancerous and non-cancerous samples during the study. This advancement not only strengthens Immunovia’s position in the market but also emphasizes the test's applicability across diverse high-risk populations, such as those with a family history of pancreatic cancer, genetic predispositions, diabetes, or existing pancreatic cysts.
In a remarkable first, combined results from both the VERIFI and the preceding CLARITI validation studies provide a comprehensive view of the test’s performance across various groups of high-risk patients. According to the data, the test demonstrated consistent sensitivity and specificity that can aid in the accurate detection of pancreatic cancer for individuals categorized into different high-risk groups. The overall results reveal that from a total of 317 cases and 1,134 controls, the test achieved a sensitivity of 78% along with an impressive specificity of 92%.
Breaking down the results further highlights the test’s efficiency in specific demographics. For individuals with a familial or genetic risk factor, sensitivity remained at 78% with a specificity of 94%. In patients suffering from diabetes, the sensitivity reached 80%, with a specificity of 90%. Lastly, individuals with pancreatic cysts saw sensitivity at 72% and specificity at 89%.
What stands out is that the specificity observed in the VERIFI study aligns closely with the performance benchmark set by CA19-9, only slightly below the target of 90% with Immunovia’s test recording a specificity of 88%. Borcherding reiterated the significance of this achievement, asserting that such promising accuracy data enhances Immunovia’s commercial prospects and broadens the market it can serve.
Looking to the future, Immunovia is gearing up for the commercial launch of its pancreatic cancer blood test, expected in the third quarter of 2025. The company is committed to conducting further clinical studies to validate the clinical impact of this groundbreaking test and establish its efficacy in other high-risk populations. These forthcoming studies will not only support important regulatory filings but also drive the company's efforts in securing payer reimbursement to facilitate broader access to this vital testing. Alongside these developments, Immunovia is seeking potential commercial partnerships to expedite the uptake of its revolutionary test in the healthcare market.
The VERIFI study itself, which involved the analysis of 385 blood samples collected from six prominent pancreatic cancer research centers across the United States, underlines the rigor behind the research methodology. Among those samples, a total of 115 originated from patients diagnosed with stage I and II pancreatic ductal adenocarcinoma, commonly regarded as the predominant form of pancreatic cancer. These were effectively contrasted with 270 control samples from high-risk individuals who did not have the disease, including those with relevant family histories, gene mutations, or existing pancreatic cysts.
Pancreatic cancer continues to pose a significant threat, marked by a grim five-year survival rate of only 13%. As such, early detection remains a cornerstone for improving patient outcomes. Immunovia's dedication to developing this next-generation test is a crucial step in equipping healthcare professionals with the necessary tools to identify this disease in its nascent stages, particularly for individuals with heightened risks due to genetic factors or previously existing pancreatic conditions. The company estimates over 1.8 million individuals in the United States are at a high-risk threshold for pancreatic cancer, indicating a robust market demand for their innovation.
In conclusion, Immunovia is at the forefront of a paradigm shift in pancreatic cancer diagnostics, committed to enhancing survival through early detection. The testimonies from the success of the VERIFI study mark a significant milestone for the company and offer hope for countless patients at risk. For more details or inquiries, interested parties can contact Jeff Borcherding, CEO and President of Immunovia, through the provided contact channels, or visit their official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.